6 2 µg of IRF-1-dependent luciferase reporter plasmid (Panomics, Inc., Fremont, CA), and/or 100 116 nM with the combination of three different Silencer Pre-designed small interfering RNA 117 (siRNA) GRIP-1 (CACAGGAAUGAUUGGUAA, GGAGAUUGAUAGAGCCUUA, 118 GACAAGGGUUGAAUAUGA) (Santa Cruz Biotechnology, Santa Cruz, CA), and 1 µg of β-119 galactosidase vector (used to normalize transfection efficiency) (Promega, Madison, WI). 120
Controls included the parallel use of pcDNA3 empty vector (Stratagene, La Jolla, CA) and/or 121 scramble nonsilencing siRNA (Santa Cruz Biotechnology). The activities of luciferase and β-122 galactosidase were evaluated using luciferase and β-galactosidase detection kits (Promega), 123 respectively, according to the manufacturer's instructions (14). The reporter luciferase activities 124 were normalized to β-galactosidase activity and expressed as relative luminescence unit (RLU). 125
Data were then expressed as percentage of controls (means ± SEM). 126
Immunoblot Analysis. Immunoblot analysis for GRIP-1, IRF-1 and GR was performed as 127 described previously (14). To ensure equal loading, the membranes were stripped and reprobed 128 with anti-β-actin antibody (Santa Cruz Biotechnology). Immunoprecipitations using the IRF-1, 129 GRIP-1 (Santa Cruz Biotechnology) and GR antibodies (Affinity BioReagents, Golden, CO) 130 were performed as previously described (14) . 131
In vitro Binding. Glutathione S-Transferase (GST)-tagged IRF-1 was expressed in Escherichia 132 coli, purified and tested for its ability to interact with in vitro transcribed/translated GRIP-1 133 derivatives as previously described (21). The gels were stained with Coomassie blue (not shown) 134 and autoradiographed. 135
RT-PCR Analysis. Total RNAs were extracted from human ASM cells using RNeasy Mini Kit 136 (Qiagen, Valencia, CA) as previously described (14) using CD38, MPK-1 and GAPDH primers 137 as reported earlier (14, 24, 25). GRIP-1 primers were purchased from Santa Cruz Biotechnology.
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In preliminary experiments, we determined, for each primer pair, the melting temperature and 139 number of amplification cycles necessary to yield the appropriate PCR product size. 
GRIP-1 is essential for GR-dependent gene transcription in ASM cells. Although GCs 156
suppress activities of some but not all cytokine-induced inflammatory genes (11), the underlying 157 molecular mechanisms appear complex since GC actions are highly promoter-and cell type-158 specific (13). Although GRIP-1 is a well-established GR receptor co-activator, its role in GC 159 function is also complex as it can affect both GR transactivation and transrepression activities 160 (19). As shown in Figure 1A , GRIP-1 was expressed in ASM whole cell extracts, and that 161 We next investigated whether GRIP-1 recruitment to IRF-1 is functional and investigated 210 whether manipulating GRIP-1 levels modulates IRF-1 transactivation activities. The use of 211 silencing strategies demonstrated that the siRNA to GRIP-1 (but not siRNA controls) reduced by 212 more than 57% TNFα/IFNγ-induced IRF-1-dependent reporter gene activity ( Figure 2C ). GRIP-213 1 depletion also abrogated the expression of CD38, an IRF-1-dependent gene in ASM cells (14) 214 as shown by the 47% reduction of cytokine-induced CD38 mRNA up-regulation ( Figure 2D Figure 3A ). This suppression, however, was no 231 longer observed in cells ove-rexpressing GRIP-1 ( Figure 3A) . Similarly, when steroid 232 insensitivity was induced by over-expressing IRF-1, increased levels of GRIP-1 restored GR 233 reporter activity in IRF-1-transfected cells ( Figure 3B ). Of note, GRIP-1 over-expression 234 dramatically and efficiently increased GRIP-1 protein contents (by 2.2 fold, data not shown). 235
These findings suggest that inflammatory cytokines promote GC insensitivity via activation of 236 IRF-1 that associates GRIP-1 and sequesters GRIP-1 away from GR. This represents a potential 237 molecular mechanism underlying steroid insensitivity induced by inflammatory cytokines. function. Our study also shows that the induction of anti-inflammatory proteins such as MKP-1 253
